Karyopharm Therapeutics Inc.
KPTINasdaq
$9.51
↑ +1.4%Jul 17 close · end-of-day
Price
1Y↑ +127.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$235,039.65
Enterprise Value
-$90.6M
P/E
—
P/S
0.0
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$151.1M
Net Income (TTM)
-$195.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-55.7%
Net Margin
-129.0%
ROE
73.4%
ROIC
—
Debt / Equity
—
Net Cash
$90.8M
Return 1Y
+133.7%
Company profile
Karyopharm Therapeutics Inc. discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries.
- CEO
- Richard A. Paulson
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 380
- Headquarters
- Massachusetts
- Website
- karyopharm.com
Management & directors
- Abate KristinChief Accounting Officer
- Cheng Sohanya RoshanEVP & Chief Commercial Officer
- Mano MichaelSVP, General Counsel&Secretary
- Paulson Richard A.President and CEO
- Poulton StuartEVP, Chief Development Officer
- Rangwala ReshmaEVP & Chief Medical Officer
- Macomber LoriEVP, CFO & Treasurer
Roles derived from SEC Form 4 filings.
Earnings
KPTI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$35.1M↑ +16.8%
Diluted EPS-$1.24↓ -55.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $108.1M | $209.8M | $157.1M | $146.0M | $145.2M | $146.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$171.8M | -$98.3M | -$142.2M | -$129.5M | -$119.4M | -$90.7M |
| Net income | -$196.3M | -$124.1M | -$165.3M | -$143.1M | -$76.4M | -$196.0M |
| Diluted EPS | -$2.72 | -$1.65 | -$2.02 | -$18.79 | -$14.00 | -$17.93 |
| Operating cash flow | -$160.2M | -$107.1M | -$149.6M | -$92.7M | -$127.5M | -$75.4M |
| Free cash flow | -$160.4M | -$107.3M | -$149.7M | -$92.7M | -$127.6M | -$75.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -159.0% | -46.8% | -90.5% | -88.7% | -82.2% | -62.1% |
| Net margin | -181.6% | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $42.8M | $38.8M | $30.5M | $30.0M | $37.9M | $44.0M | $34.1M | $35.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$28.1M | -$26.3M | -$31.3M | -$33.3M | -$24.4M | -$15.2M | -$17.8M | -$26.8M |
| Net income | $23.8M | -$32.1M | -$30.8M | -$23.5M | -$37.3M | -$33.1M | -$102.2M | -$22.4M |
| Diluted EPS | -$2.97 | -$3.85 | -$2.33 | -$2.77 | -$4.32 | -$3.82 | -$7.02 | -$1.24 |
| Operating cash flow | -$38.5M | -$19.5M | -$25.8M | -$39.0M | -$18.7M | -$5.9M | -$11.8M | -$22.7M |
| Free cash flow | -$38.5M | -$19.5M | -$25.9M | -$39.0M | -$18.7M | -$5.9M | -$11.8M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -65.7% | -67.8% | -102.4% | -110.8% | -64.3% | -34.6% | -52.4% | -76.3% |
| Net margin | 55.6% | -82.7% | -100.8% | -78.2% | -98.2% | -75.2% | -299.9% | -63.9% |
Company news
Jun 14, 2026
- 36d agoMenarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congressfinance.yahoo.com
- 36d agoMenarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congressfinance.yahoo.com
Jun 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-21 | PAKIANATHAN DEEPIKA | Award | 15,508 | $0.00 | $0.00 | filing |
| 2026-05-21 | Oliger Christy J. | Award | 15,508 | $0.00 | $0.00 | filing |
| 2026-05-21 | Schor Chen | Award | 15,508 | $0.00 | $0.00 | filing |
| 2026-05-21 | Su Zhen | Award | 15,508 | $0.00 | $0.00 | filing |
| 2026-05-21 | BOHLIN GAREN G | Award | 15,508 | $0.00 | $0.00 | filing |
| 2026-05-21 | Greene Barry E | Award | 15,508 | $0.00 | $0.00 | filing |
| 2026-05-14 | Paulson Richard A.· President and CEO | Sale | 2,203 | $9.50 | $20,928.50 | filing |
| 2026-05-14 | Rangwala Reshma· EVP & Chief Medical Officer | Sale | 408 | $9.50 | $3,876.00 | filing |
| 2026-05-14 | Poulton Stuart· EVP, Chief Development Officer | Sale | 403 | $9.50 | $3,828.50 | filing |
| 2026-05-14 | Cheng Sohanya Roshan· EVP & Chief Commercial Officer | Sale | 324 | $9.50 | $3,078.00 | filing |
| 2026-05-14 | Mano Michael· EVP, CLO&Secretary | Sale | 266 | $9.50 | $2,527.00 | filing |
| 2026-05-14 | Abate Kristin· Chief Accounting Officer | Sale | 53 | $9.50 | $503.50 | filing |
| 2026-05-13 | Rangwala Reshma· EVP & Chief Medical Officer | Award | 947 | $0.00 | $0.00 | filing |
| 2026-05-13 | Poulton Stuart· EVP, Chief Development Officer | Award | 896 | $0.00 | $0.00 | filing |
| 2026-05-13 | Cheng Sohanya Roshan· EVP & Chief Commercial Officer | Award | 947 | $0.00 | $0.00 | filing |
| 2026-05-13 | Abate Kristin· Chief Accounting Officer | Award | 121 | $0.00 | $0.00 | filing |
| 2026-05-13 | Paulson Richard A.· President and CEO | Award | 4,920 | $0.00 | $0.00 | filing |
| 2026-05-13 | Mano Michael· EVP, CLO&Secretary | Award | 700 | $0.00 | $0.00 | filing |
| 2026-04-21 | Rangwala Reshma· EVP & Chief Medical Officer | Sale | 449 | $8.94 | $4,014.06 | filing |
| 2026-03-02 | Paulson Richard A.· President and CEO | Sale | 12,361 | $9.41 | $116,310.83 | filing |
| 2026-03-02 | Poulton Stuart· EVP, Chief Development Officer | Sale | 5,101 | $9.41 | $47,997.86 | filing |
| 2026-03-02 | Rangwala Reshma· EVP & Chief Medical Officer | Sale | 5,066 | $9.41 | $47,668.53 | filing |
| 2026-03-02 | Cheng Sohanya Roshan· EVP & Chief Commercial Officer | Sale | 4,604 | $9.41 | $43,321.34 | filing |
| 2026-03-02 | Mano Michael· EVP, CLO&Secretary | Sale | 3,526 | $9.41 | $33,177.90 | filing |
| 2026-03-02 | Abate Kristin· Chief Accounting Officer | Sale | 559 | $9.41 | $5,259.91 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.